Baseline characteristics and disease severity of sepsis patients stratified according to platelet counts on ICU admission
| . | Very low (<50 × 109/L) . | Intermediate-low (50 × 109 to 99 × 109/L) . | Low (100 × 109 to 149 × 109/L) . | Normal (150 × 109 to 399 × 109/L) . | P . |
|---|---|---|---|---|---|
| Patients, n (%) | 61 (6.6%) | 121 (13.0%) | 167 (17.9%) | 580 (62.3%) | |
| Demographics | |||||
| Age (years), mean (SD) | 56.4 (14.6)*† | 58.5 (16.4)* | 62.2 (13.9) | 62.6 (14.4) | .002 |
| Gender male, n (%) | 34 (55.7%) | 66 (54.5%) | 112 (67.1%) | 349 (60.2%) | .14 |
| White race, n (%) | 52 (85.2%) | 105 (86.8%) | 147 (88%) | 509 (87.8%) | .41 |
| Chronic comorbidity | |||||
| Modified Charlson comorbidity index,§ median (IQR) | 0 (0-1)*† | 1 (0-2)† | 1 (0-3) | 1 (0-2) | .0002 |
| Cardiovascular insufficiency, n (%) | 9 (14.8%)† | 27 (22.3%) | 55 (32.9%) | 146 (25.2%) | .03 |
| Chronic obstructive pulmonary disease, n (%) | 5 (8.2%) | 11 (9.1%) | 24 (14.4%) | 100 (17.2%) | .05 |
| Diabetes mellitus, n (%) | 7 (11.5%) | 21 (17.4%) | 38 (22.8%) | 121 (20.9%) | .22 |
| Hypertension, n (%) | 9 (14.8%)*† | 35 (28.9%) | 59 (35.3%) | 191 (32.9%) | .02 |
| Malignancy, n (%) | 6 (9.8%) | 16 (13.2%) | 31 (18.6%) | 113 (19.5%) | .13 |
| Peripheral vascular disease, n (%) | 6 (9.8%) | 17 (14.0%) | 34 (20.4%)* | 69 (11.9%) | .03 |
| Renal insufficiency, n (%) | 11 (18.0%) | 22 (18.2%) | 27 (16.2%) | 86 (14.8%) | .76 |
| Use of antiplatelet drugs¶, n (%) | 10 (16.4%) | 31 (25.6%) | 49 (29.3%) | 172 (29.7%) | .27 |
| Medical admission type, n (%) | 53 (86.9%)*†‡ | 83 (68.6%) | 113 (67.7%) | 425 (73.3%) | .02 |
| Primary source of infection, n (%) | |||||
| Respiratory tract | 22 (36.1%)* | 37 (30.6%)* | 63 (37.7%)* | 305 (52.6%) | .001 |
| Abdomen | 16 (26.2%) | 35 (28.9%) | 37 (22.2%) | 116 (20.0%) | .16 |
| Cardiovascular | 8 (13.1%) | 19 (15.7%) | 29 (17.4%) | 80 (13.8%) | .63 |
| Urinary tract | 10 (16.4%) | 23 (19.0%)* | 27 (16.2%) | 57 (9.8%) | .01 |
| Skin | 5 (8.2%) | 7 (5.8%) | 11 (6.6%) | 22 (3.8%) | .23 |
| Severity of disease | |||||
| APACHE IV score, median (IQR) | 104 (84-131)*†‡ | 85 (69-112)† | 77 (63-99) | 76 (60-94) | <.0001 |
| APACHE IV APS, median (IQR) | 89 (73-119)*†‡ | 75 (55-94)*† | 65 (50-85) | 64 (48-79) | <.0001 |
| Modified SOFA‖, median (IQR) | 10 (7-12)*† | 8 (6-10)*† | 7 (5-9)* | 7 (4-8) | <.0001 |
| Septic shock, n (%) | 33 (54.1%)*† | 60 (49.6%)*† | 62 (37.1%)* | 165 (28.4%) | .001 |
| Mechanical ventilation, n (%) | 44 (72.1%) | 85 (70.2%) | 115 (68.9%) | 406 (70%) | .98 |
| Organ failure, n (%) | 53 (86.9%) | 100 (82.6%) | 143 (85.6%) | 479 (82.6%) | .20 |
| Acute kidney injury, n (%) | 34 (55.7%)* | 61 (50.4%)* | 75 (44.9%)* | 177 (30.5%) | .001 |
| Acute lung injury, n (%) | 22 (36.1%) | 36 (29.8%) | 38 (22.8%) | 132 (22.8%) | .07 |
| . | Very low (<50 × 109/L) . | Intermediate-low (50 × 109 to 99 × 109/L) . | Low (100 × 109 to 149 × 109/L) . | Normal (150 × 109 to 399 × 109/L) . | P . |
|---|---|---|---|---|---|
| Patients, n (%) | 61 (6.6%) | 121 (13.0%) | 167 (17.9%) | 580 (62.3%) | |
| Demographics | |||||
| Age (years), mean (SD) | 56.4 (14.6)*† | 58.5 (16.4)* | 62.2 (13.9) | 62.6 (14.4) | .002 |
| Gender male, n (%) | 34 (55.7%) | 66 (54.5%) | 112 (67.1%) | 349 (60.2%) | .14 |
| White race, n (%) | 52 (85.2%) | 105 (86.8%) | 147 (88%) | 509 (87.8%) | .41 |
| Chronic comorbidity | |||||
| Modified Charlson comorbidity index,§ median (IQR) | 0 (0-1)*† | 1 (0-2)† | 1 (0-3) | 1 (0-2) | .0002 |
| Cardiovascular insufficiency, n (%) | 9 (14.8%)† | 27 (22.3%) | 55 (32.9%) | 146 (25.2%) | .03 |
| Chronic obstructive pulmonary disease, n (%) | 5 (8.2%) | 11 (9.1%) | 24 (14.4%) | 100 (17.2%) | .05 |
| Diabetes mellitus, n (%) | 7 (11.5%) | 21 (17.4%) | 38 (22.8%) | 121 (20.9%) | .22 |
| Hypertension, n (%) | 9 (14.8%)*† | 35 (28.9%) | 59 (35.3%) | 191 (32.9%) | .02 |
| Malignancy, n (%) | 6 (9.8%) | 16 (13.2%) | 31 (18.6%) | 113 (19.5%) | .13 |
| Peripheral vascular disease, n (%) | 6 (9.8%) | 17 (14.0%) | 34 (20.4%)* | 69 (11.9%) | .03 |
| Renal insufficiency, n (%) | 11 (18.0%) | 22 (18.2%) | 27 (16.2%) | 86 (14.8%) | .76 |
| Use of antiplatelet drugs¶, n (%) | 10 (16.4%) | 31 (25.6%) | 49 (29.3%) | 172 (29.7%) | .27 |
| Medical admission type, n (%) | 53 (86.9%)*†‡ | 83 (68.6%) | 113 (67.7%) | 425 (73.3%) | .02 |
| Primary source of infection, n (%) | |||||
| Respiratory tract | 22 (36.1%)* | 37 (30.6%)* | 63 (37.7%)* | 305 (52.6%) | .001 |
| Abdomen | 16 (26.2%) | 35 (28.9%) | 37 (22.2%) | 116 (20.0%) | .16 |
| Cardiovascular | 8 (13.1%) | 19 (15.7%) | 29 (17.4%) | 80 (13.8%) | .63 |
| Urinary tract | 10 (16.4%) | 23 (19.0%)* | 27 (16.2%) | 57 (9.8%) | .01 |
| Skin | 5 (8.2%) | 7 (5.8%) | 11 (6.6%) | 22 (3.8%) | .23 |
| Severity of disease | |||||
| APACHE IV score, median (IQR) | 104 (84-131)*†‡ | 85 (69-112)† | 77 (63-99) | 76 (60-94) | <.0001 |
| APACHE IV APS, median (IQR) | 89 (73-119)*†‡ | 75 (55-94)*† | 65 (50-85) | 64 (48-79) | <.0001 |
| Modified SOFA‖, median (IQR) | 10 (7-12)*† | 8 (6-10)*† | 7 (5-9)* | 7 (4-8) | <.0001 |
| Septic shock, n (%) | 33 (54.1%)*† | 60 (49.6%)*† | 62 (37.1%)* | 165 (28.4%) | .001 |
| Mechanical ventilation, n (%) | 44 (72.1%) | 85 (70.2%) | 115 (68.9%) | 406 (70%) | .98 |
| Organ failure, n (%) | 53 (86.9%) | 100 (82.6%) | 143 (85.6%) | 479 (82.6%) | .20 |
| Acute kidney injury, n (%) | 34 (55.7%)* | 61 (50.4%)* | 75 (44.9%)* | 177 (30.5%) | .001 |
| Acute lung injury, n (%) | 22 (36.1%) | 36 (29.8%) | 38 (22.8%) | 132 (22.8%) | .07 |
Significant vs normal platelet count (150 × 109 to 399 × 109/L) using a Dunn's Test of multiple comparisons using rank sums.
Significant vs low platelet count (100 × 109 to 149 × 109/L) using a Dunn's Test of multiple comparisons using rank sums.
Significant vs intermediate-low platelet count (50 × 109 to 99 × 109/L) using a Dunn's Test of multiple comparisons using rank sums.
Modified Charlson comorbidity was calculated without the contribution of age.
Modified SOFA was calculated without the contribution of SOFA coagulation and SOFA central nervous system.
Use of antiplatelet drugs: use prior to ICU admission as chronic medication (carbasalate calcium, acetylsalicylic acid, clopidogrel, dipyridamol).